AMENDMENTS

Please enter the following amendments without prejudice or disclaimer.

In the claims:

Please amend claims 33, 39-42, 45, 47-50, 54, 60-62 and 64 as follows.

33. (Amended) A method of treating a disease responsive to a biologically active molecule in a mammal, comprising:

creating an immune-privileged site in a mammal by administering an effective amount of retinal pigment epithelial (RPE) cells and co-administering to the site a population of non-RPE cells that supplies the biologically active molecule that is deficient in the disease in an amount effective to sustain a therapeutic effect, wherein said non-RPE cell population is allogeneic to the mammal.

39. (Amended) The method of claim 33 wherein said population of non-RPE cells is transformed by a nucleic acid encoding said biologically active molecule and wherein said biologically active molecule is a biologically active protein.

40. (Amended) The method of claim 33 wherein said RPE cells are transformed by a nucleic acid encoding a biologically active protein.

41. (Amended) The method of claim 33 wherein said RPE cells or said cells of said non-RPE cell population are attached to a matrix prior to administration.

42. (Amended) The method of claim 33 wherein said RPE cells and said cells of said non-RPE cell population are attached to a matrix prior to administration.

45. (Amended) The method of claim 33 wherein said non-RPE cell population is co-administered in a dose ranging from 10^3 to 10^7 cells.

47. (Amended) The method of claim 33, further comprising re-administering RPE cells or cells of said non-RPE cell population to the site in an effective amount to sustain a therapeutic effect.

48. (Amended) The method of claim 33 further comprising re-administering RPE cells and cells of said non-RPE cell population in amounts effective to sustain a therapeutic effect, wherein the RPE cells and the cells of the non-RPE cell population are attached to a matrix prior to re-administration.

49. (Amended) The method according to claim 33 wherein the RPE cells and the non-RPE cell population are co-administered as a single composition.

50. (Amended) The method according to claim 33 wherein the RPE cells and the non-RPE cell population are co-administered as separate compositions.

54. (Amended) A pharmaceutical composition comprising retinal pigment epithelial (RPE) cells, a non-RPE cell population, and a pharmaceutically acceptable carrier,

wherein said non-RPE cell population is allogeneic to said RPE cells and wherein said non-RPE cell population produces a biologically active molecule that is absent or defective in a disease.

60. (Amended) A pharmaceutical composition comprising retinal pigment epithelial (RPE) cells and a non-RPE cell population, wherein said non-RPE cell population is allogeneic to said RPE cells, wherein said non-RPE cell population produces a biologically active molecule